Yahoo Finance

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.

Don't Miss Our New Year's Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CTXR:

• Citius Pharma Reports 2024 Financial Results and Business Update

• Citius Pharmaceuticals trading halted, news pending

• Citius Pharmaceuticals reports ‘constructive’ FDA Type C meeting on Mino-Lok

• Citius Pharmaceuticals downgraded to Hold from Buy at D. Boral Capital

• Citius Pharmaceuticals announces 1-for-25 reverse stock split